

**Amendments to the Claims:**

Please amend claims 40, 42, 43, 45, 55 and 56 and cancel claims 1-36, as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-37. (Canceled).

38. (Previously Presented) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:  
implanting a vascular prosthesis in the blood vessel; and  
releasing methylprednisolone from the prosthesis at a rate between 5  $\mu\text{g}/\text{day}$  to 200  $\mu\text{g}/\text{day}$ .

39. (Previously Presented) A method as in claim 38, wherein methylprednisolone is released at a rate between 10  $\mu\text{g}/\text{day}$  to 60  $\mu\text{g}/\text{day}$ .

40. (Currently Amended) A method as in claim 38, wherein for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:

~~implanting a vascular prosthesis in the blood vessel; and,~~  
~~releasing methylprednisolone is released~~ from the prosthesis within a time period of 1 day to 45 days in a vascular environment.

41. (Previously presented) A method as in claim 40, wherein methylprednisolone is released within a time period of 7 days to 21 days in a vascular environment.

42. (Currently Amended) A method as in claim 38, further comprising for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:

~~implanting a vascular prosthesis in the blood vessel; and~~  
~~releasing methylprednisolone and at least one other substance simultaneously~~  
with methylprednisolone from the prosthesis.

43. (Currently Amended) A method as in claim 38, ~~for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:~~

~~implanting a vascular prosthesis in the blood vessel; and~~  
~~releasing methylprednisolone and at least one other substance sequentially with~~  
methylprednisolone from the prosthesis.

44. (Original) A method as in claim 42 or 43, wherein the at least one additional substance is an immunosuppressive substance selected from the group consisting of rapamycin, mycophenolic acid, riboflavin, tiazofurin, mizoribine, FK 506, zafurin, and methotrexate.

45. (Currently Amended) A method as in claim 38, ~~for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:~~

~~implanting a vascular prosthesis in the blood vessel; and~~  
~~releasing methylprednisolone wherein the releasing comprises delaying~~  
substantial release of methylprednisolone for at least one hour following implantation of the prosthesis.

46. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone from a reservoir with a material that at least partially degrades in a vascular environment over said one hour.

47. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a matrix that at least partially degrades in a vascular environment over said one hour.

48. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a nondegradable matrix that allows diffusion of methylprednisolone through the nondegradable matrix after said one hour.

49. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a rate limiting barrier that allows diffusion of methylprednisolone through the barrier after said one hour.

50. (Original) A method as in any one of claims 47-49, wherein the prosthesis is coated with the matrix or barrier by spraying, dipping, deposition, or painting.

51.-53. (Canceled).

54. (Previously Presented) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:  
implanting a vascular prosthesis in the blood vessel; and  
releasing methylprednisolone and mycophenolic acid from the prosthesis when implanted in the blood vessel.

55. (Currently Amended) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:  
implanting a vascular prosthesis in the blood vessel; and  
releasing methylprednisolone and at least one other substance in addition to methylprednisolone from the prosthesis when implanted in the blood vessel, wherein the at least one other substance is comprises mizoribine.

56. (Currently Amended) A method as in claim 38, further comprising for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:  
~~implanting a vascular prosthesis in the blood vessel; and~~

releasing methylprednisolone and at least one other substance in addition to methylprednisolone from the prosthesis when implanted in the blood vessel, wherein methylprednisolone is substantially released within a time period of 2 days to 3 months.

57. (Previously Presented) A method as in claim 56, wherein the at least one additional substance comprises at least one agent selected from the group consisting of anti-platelet agent, anti-thrombotic agent, and IIb/IIIa agent.

58. (Previously Presented) A method as in claim 56, wherein methylprednisolone and the at least one additional substance are released simultaneously.

59. (Previously Presented) A method as in claim 56, wherein methylprednisolone and the at least one additional substance are released sequentially.

60.-61. (Canceled).